An abstract from Science News This Week (Dec. 13).
[[ Jon Cohen
A new, remarkably powerful drug that cripples the hepatitis C virus (HCV) came to market last week, but it sells for $1000 per pill. The drug, sofosbuvir, must be combined with other drugs and used for 12 weeks to cure an infection, a regimen that only wealthy countries can afford. Advocates are urging Gilead Sciences, sofosbuvir's manufacturer, to sell the drug at a steep discount to cash-strapped countries, which are home to more than 100 million HCV-infected people. And they want Gilead to offer this differential pricing today, not several years from now, as happened with the anti-HIV drugs that revolutionized AIDS treatment.]]
I wanted point out that global opportunities for [VX-135 + Daclatasvir] and [VX-135 + Simeprevir] are enormous. Even if the SVRs turn out to be less than 90% and prices are discounted, they can generate multibillion dollars for Vertex, J&J, and Bristol. Analysts and the market do not assign any value to pangenomic VX-135. That does NOT mean that VX-135 has no value.